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BRIEF REPORT
Whole-Exome Sequencing Revealing Somatic NLRP3 Mosaicism in a Patient
With Chronic Infantile Neurologic, Cutaneous, Articular Syndrome
Ebun Omoyinmi,1 So´nia Melo Gomes,1 Ariane Standing,1 Dorota M. Rowczenio,2 Despina Eleftheriou,1
Nigel Klein,1 Juan I. Aro´stegui,3 Helen J. Lachmann,2 Philip N. Hawkins,2 and Paul A. Brogan1
Objective. To identify the genetic cause of chronic
infantile neurologic, cutaneous, articular syndrome
(CINCA syndrome) using whole-exome sequencing in a
child who had typical clinical features but who was
NLRP3 mutation negative based on conventional Sanger
sequencing.
Methods. We performed whole-exome sequencing
on DNA from peripheral blood, using Illumina TruSeq
Exome capture and the HiSeq sequencing platform.
Exome data were analyzed in the Galaxy Web-based
suite. Whole-exome sequencing findings were confirmed
by massively parallel sequencing.
Results. Analysis of variants in known autoin-
flammatory genes led to the identification of the patho-
genic p.F556L NLRP3 missense mutation in 17.7% of
Illumina reads (25 of 141). No new candidate genes were
identified. Massively parallel sequencing of DNA from
peripheral blood (performed in duplicate) unequivo-
cally confirmed the presence of this mutation in 14.5%
of alleles. Reexamination of the original Sanger chro-
matograms revealed a small peak at nucleotide position
c.1698 corresponding to the mutated allele. This had
initially been regarded as background noise, but in
retrospect is completely consistent with somatic mosa-
icism for the p.F556L NLRP3 mutation in this child with
CINCA syndrome.
Conclusion. This is the first description of so-
matic NLRP3 mosaicism detected using whole-exome
sequencing in a “mutation-negative” patient with
CINCA syndrome. Our findings suggest that whole-
exome sequencing could be an important diagnostic tool
for detecting somatic mosaicism, as well as for the
discovery of novel causative gene mutations, in patients
with clinical features of cryopyrin-associated periodic
syndromes who are NLRP3 mutation negative by con-
ventional sequencing. This approach could also be
applicable to patients with other autosomal-dominant
autoinflammatory diseases characterized by gain-of-
function mutations who are mutation negative by con-
ventional Sanger sequencing.
Cryopyrin-associated periodic syndromes
(CAPS) comprise a spectrum of autoinflammatory dis-
eases with 3 overlapping clinical entities of increasing
disease severity: familial cold autoinflammatory syn-
drome, Muckle-Wells syndrome, and chronic infantile
neurologic, cutaneous, articular syndrome (CINCA syn-
drome). CINCA syndrome represents the most severe
form, with continuous inflammatory disease activity
from birth associated with a generalized urticaria-like
skin rash, dysmorphic features, deforming arthropathy,
chronic aseptic meningitis, increased intracranial pres-
sure, variable neurologic deficits, papilledema, senso-
rineural hearing loss, and poor growth (1).
The only genetic cause of CAPS that has been
identified to date is the occurrence of heterozygous
germline mutations in NLRP3. More than 80 different
disease-causing mutations have been identified, mostly
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clustered in exon 3 but also found in exons 4 and 6,
either arising de novo or transmitted in an autosomal-
dominant manner (1,2). The NLRP3 variants detected in
CAPS are gain-of-function mutations that activate the
NLRP3 inflammasome and provoke uncontrolled over-
production of interleukin-1 (IL-1).
Up to 50% of patients with clinically diagnosed
CINCA syndrome (with identical clinical features and
response to anti–IL-1 treatment) show no NLRP3 mu-
tation when tested using conventional Sanger DNA
sequencing (2). While it is possible that such patients
harbor mutations in as-yet-unidentified genes, recent
studies suggest that somatic NLRP3 mosaicism may
account for up to 70% of the cases of apparently
“mutation-negative” CINCA syndrome (3). Since
CAPS, and particularly CINCA syndrome, is a serious
genetic illness requiring lifelong anti–IL-1 therapy with
considerable cost implications, securing a molecular
diagnosis remains an important issue for both affected
families and their health care providers. Strategies have
therefore been developed to reliably detect low-level
somatic NLRP3 mosaicism in patients with clinical fea-
tures of CAPS who are mutation negative by conven-
tional genetic screening (4). In this study we hypothe-
sized that whole-exome sequencing, an increasingly
available and potentially important diagnostic genetic
tool (5), might reveal somatic NLRP3 mosaicism and/or
identify novel candidate genes in a pediatric CINCA
syndrome patient who was NLRP3 mutation negative by
standard genetic testing.
PATIENT AND METHODS
Case description. The patient, an 8-year-old boy who
had typical clinical features of CINCA syndrome and had been
found on earlier testing to be NLRP3 mutation negative, was
referred for specialist consultation at the national CAPS
clinical service at Great Ormond Street Hospital NHS Foun-
dation Trust, London, UK. He was the first child of noncon-
sanguineous parents of Scottish ancestry. He was born prema-
turely at 27 weeks’ gestation, requiring early ventilatory
support. At birth he was noted to have frontal skull bossing and
midfacial hypoplasia, and he developed an intermittent urti-
carial skin rash over his face and limbs. During his first year of
life he was frequently hospitalized due to fever, urticarial skin
rash (Figure 1A), and elevated acute-phase reactant levels,
without an infectious cause. An extensive evaluation for pri-
mary immunodeficiency and autoimmunity yielded negative
results; karyotype was normal (46XY). At age 18 months he
was diagnosed as having CINCA syndrome based on the
above-mentioned clinical features and the additional presence
of synovitis of both knees with fixed flexion deformity and bony
overgrowth of the left patella and tibia (Figure 1C). He had
severe failure to thrive and motor developmental delay. Mo-
lecular genetic screening for NLRP3 mutations revealed the
wild type for exons 3, 4, and 6.
Initial treatment with oral prednisolone (2 mg/kg/day)
partially improved the rash and the patient’s general well-
being; anakinra (2 mg/kg/day) elicited a partial clinical re-
sponse and modest steroid-sparing effect, but his clinical
symptoms and serum amyloid A (SAA) levels were never well
controlled. At age 5 years, he had an epileptic seizure. Mag-
netic resonance imaging of the brain showed focal cortical
dysplasia of the right middle frontal gyrus. Audiography re-
vealed mild (30-db) conductive hearing loss, but no senso-
rineural loss. Regular and frequent screening had excluded
inflammatory eye disease. Anakinra was switched to canaki-
Figure 1. Clinical features of chronic infantile neurologic, cutaneous, articular syndrome in the patient. A, Persistent urticaria-like skin rash despite
canakinumab treatment (4 mg/kg every 8 weeks). At the time this photograph was taken (when the patient was 7 years old), the cryopyrin-associated
periodic syndromes Disease Activity Score (DAS) was 11 of 20, and the serum amyloid A (SAA) level was elevated at 154 mg/liter (normal 10).
B, Improvement of the skin rash 8 weeks after the dosage of canakinumab was increased to 8 mg/kg every 8 weeks. At the time this photograph was
taken, the DAS had declined to 1 of 20, but the SAA level was still elevated at 118 mg/liter. C, Patellar and tibial bony overgrowth, seen on a
radiograph obtained when the patient was 7 years old.
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numab (4 mg/kg subcutaneously every 8 weeks) when the
patient was age 7 years, because of ongoing disease activity
(CAPS disease activity score [DAS] [6] 11 of 20) and an SAA
level of 154 mg/liter (normal 10) despite treatment with
prednisolone 1 mg/kg/day. Although there was an initial good
clinical response to canakinumab at this starting dosage, the
symptoms quickly returned. The dosage was therefore in-
creased by 2 mg/kg every 8 weeks. The CAPS DAS remained
unchanged until the canakinumab dosage reached 8 mg/kg
every 8 weeks, at which point the DAS declined to 1 of 20 (with
notable improvement of the skin rash, fevers, arthralgia,
myalgia, headaches, and energy levels) (Figure 1B), and the
prednisolone was tapered and then discontinued completely.
The SAA level remained elevated (118 mg/liter) despite this
marked clinical improvement, and increasing the frequency of
canakinumab to once every 4 weeks is currently being consid-
ered.
Ethics compliance. This study had the full approval of
the medical ethics committee of Great Ormond Street Hospi-
tal NHS Foundation Trust. Fully informed written consent was
obtained from the patient’s parents in accordance with the
Declaration of Helsinki.
DNA extraction. Genomic DNA was extracted from
peripheral blood using a QIAamp DNA Blood Mini kit
according to the instructions of the manufacturer (Qiagen).
Whole-exome sequencing. Libraries were generated
from DNA extracted from whole blood, using an Illumina
TruSeq sample preparation kit. Whole exomes were captured
using an Illumina TruSeq Exome enrichment kit and then
sequenced using an Illumina HiSeq next-generation se-
quencer. Exome data were analyzed using the Galaxy Web-
based suite (http://galaxyproject.org/) (7–9). The 100-bp
paired-end reads were mapped to the reference human ge-
nome (hg_g1k_v37) using the Burrows-Wheeler Aligner align-
ment option for Illumina. Variant calling was performed using
Genome Analysis ToolKit in Galaxy. We used wANNOVAR
(10,11), a Web server package, to annotate all of the variants
identified with Genome Analysis ToolKit. The annotated file
was used to retrieve the reference single-nucleotide polymor-
phism (SNP) identifier numbers for variants from the Single
Nucleotide Polymorphism Database (dbSNP), version 135 and
the allele frequencies in 2 publicly available databases: the
1000 Genomes Project, containing genetic variations from
1,092 human genomes, and the Exome Sequencing Project
(ESP 5400; https://esp.gs.washington.edu/drupal/), which has
screened the exomes of 6,500 individuals.
Massively parallel sequencing of NLRP3. Massively
parallel DNA sequencing of all exons of the NLRP3 gene was
performed by amplification of 14 different specific pair prim-
ers, as previously described (4). All sequencing runs were
performed on a GS Junior 454 Sequencer using GS Junior
Titanium Sequencing kits (Roche). The sequences obtained
were analyzed with Amplicon Variant Analyzer software
(Roche).
Sanger sequencing. Exons 3, 4, and 6 of NLRP3/CIAS1
(NCBI RefSeqGene NC_000001.10) and exon 3 of NLRP12
(NCBI RefSeqGene NC_000019.9) were amplified using pre-
viously described primers and conditions (12). Negative and
positive controls were included in each run. Polymerase chain
reaction (PCR) findings were validated by gel electrophoresis,
and PCR products were purified with a QIAquick PCR puri-
fication kit according to the protocol described by the manu-
facturer (Qiagen). Sequencing reaction was performed with a
BigDye Terminator v3.1 Ready Reaction Cycle Sequencing kit
(Applied Biosystems). The electrophoretic profiles of NLRP3
sequences were analyzed on an ABI 3130xl Genetic Analyzer
using Sequencing Analysis Software, version 5.4.
RESULTS
Findings of whole-exome sequencing. Whole-
exome sequencing was performed on DNA extracted
from whole blood to identify the genetic defect in this
patient with CINCA syndrome. After synonymous vari-
ants were filtered out, there were 11,428 variants (in-
cluding 239 variants not reported in the dbSNP135) to
be examined for candidate mutations. We first examined
variants in known autoinflammatory genes (IL10,
IL10RA, IL10RB, IL1RN, IL36RN, LPIN2, MEFV,
Table 1. Identified variants in genes associated with monogenic autoinflammatory diseases, and known
frequencies in the general healthy population*
Gene
Sequence
variant
Protein
variant ESP6500 1000g2012feb
1000G European
population dbSNP135
IL10RA 1051AG R351G 0.728 0.81 0.68 rs2229113
MEFV 1306GA G436R 0.424 0.38 0.44 rs1231122
MEFV 1272TA D424E 0.406 0.66 0.56 rs1231123
MVK 155GA S52N 0.116 0.09 0.15 rs7957619
NLRP3 1698CA F566L – – – –
NLRP3 2107CA Q703K 0.035 0.02 0.04 rs35829419
NOD2 802CT P268S 0.198 0.12 0.24 rs2066842
NOD2 2863GA V955I 0.069 0.05 0.10 rs5743291
SH3BP2 464CT A155V 0.006 0.01 0.02 rs35313240
* EPS6500  the Exome Sequencing Project; 1000g2012feb  February 2012 version of the 1000
Genomes Project (1000G); dbSNP135  Single Nucleotide Polymorphism Database, version 135.
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MVK, NLRP12, NLRP3, NLRP7, NOD2, PLCG2,
PSMB8, PSTPIP1, SH3BP2, and TNFRSF1A), which
resulted in the identification of 9 nonsynonymous vari-
ants in 6 different genes (Table 1). Given the clinical
presentation of the patient, the NLRP3 p.F566L muta-
tion was the most plausible candidate variant because it
was not present in general population databases (ESP,
1000G, or dbSNP), and it was previously reported as
being the causative mutation in 2 unrelated patients with
CINCA syndrome (2). The Integrative Genomics
Viewer of the alignment file revealed the presence of
this mutation in 25 of 141 Illumina reads mapping to this
region (17.7%) (Figure 2A). No new candidate genes
were identified, and there was no evidence of mosaicism
in any of the above-mentioned known autoinflammatory
genes. No other tissue (other than blood) was available
for this study.
Findings of massively parallel sequencing. Mas-
sively parallel DNA sequencing confirmed the C-to-A
transversion at the c.1698 position of the NLRP3 gene
(GenBank RefSeq NM_001243133.1) resulting in
p.F566L mutation in the patient, with a mean allelic
frequency of the mutated allele in peripheral blood of
14.5% (mean coverage 1,151; analyses performed in
duplicate).
Findings of Sanger sequencing. Sanger sequenc-
ing of NLRP3 and NLRP12 genes had been previously
performed as part of routine clinical care of the patient,
and no pathogenic variants were identified in the ana-
lyzed exons, although the nonpathogenic variant NLRP3
Q703K was detected. There was a very small peak
corresponding to the alternate allele at the c.1698 posi-
tion of the NLRP3 gene (Figure 2B), which was associ-
ated with a decrease of the signal intensity of the
wild-type allele. The small peak was previously consid-
ered background noise, but in retrospect it was compat-
ible with somatic mosaicism for the p.F566L mutation.
DISCUSSION
A puzzling aspect of CINCA syndrome is that up
to 50% of patients may have a typical clinical phenotype,
including response to IL-1 blockade treatment, but with
no detectable NLRP3 mutation demonstrated by Sanger
sequencing, which is currently the mainstay of routine
genetic diagnostic testing. The “mutation-negative”
finding in 10–69% of these CINCA syndrome patients
may be accounted for by somatic NLRP3 mosaicism,
with markedly variable reported frequencies of the
mutated allele, ranging from 4.2% to 35.8% (3). The
remaining patients may harbor mutations in novel
gene(s). Whole-exome sequencing is a powerful new
genetic technique that was previously used for gene
discovery in novel Mendelian diseases and is being
increasingly recognized as a potent diagnostic tool (5),
including for the detection of somatic gene mutations
Figure 2. A, Illumina data from the mapped reads as visualized in Integrative Genomics Viewer, providing evidence of the presence of c.1698CA
transversion. B, Sanger chromatograms showing the subtle peak for the mutated A allele at the c.1698 position in the patient sample (arrow), but
absent in a healthy control sample.
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(13–15). To the best of our knowledge, this is the first
description of somatic NLRP3 mosaicism detected by
whole-exome sequencing in a CINCA syndrome patient
who had been found to be mutation negative with other
techniques.
The p.F566L mutation detected using whole-
exome sequencing in our patient was subsequently con-
firmed by massively parallel DNA sequencing, a tech-
nique that has been previously validated for the
detection of somatic mosaicism in CAPS and is regarded
by many as a gold standard (2). Although many patients
with somatic NLRP3 mutations may have milder clinical
phenotypes or later-onset disease (2,3), the clinical
severity of our patient’s phenotype is consistent with the
known severe clinical impact of the p.F566L mutation.
Somatic NLRP3 mosaicism for the p.F566L mutation
has been previously reported in 2 unrelated patients with
CINCA syndrome, with estimated allelic mosaicism of
11.5% and 14.6%, respectively (3). The pathologic ef-
fects of this mutation have been demonstrated through
induction of necrosis-like programmed cell death in the
human monocytic line THP-1 and ASC-dependent
NF-B activation (3). Those studies combined with the
increasing number of clinical reports confirm that so-
matic mosaicism for the p.F566L mutation can result in
the most severe CAPS phenotype, the CINCA syn-
drome.
When considering the most practical methodolo-
gies for screening for somatic mosaicism in CAPS in the
routine clinical setting, factors such as sensitivity, reli-
ability, and expense come into play. Customized tech-
niques such as massively parallel DNA sequencing un-
doubtedly have the advantage of high sensitivity (2) but
are laborious and costly, currently target only NLRP3,
and are not widely available in nonspecialized laborato-
ries. Whole-exome sequencing is increasingly being uti-
lized in a diagnostic capacity at relatively low cost (5),
and we propose that it could be a valid alternative. Our
approach of using whole-exome sequencing to rapidly
screen several known autoinflammatory genes is one
that has been used successfully in other clinical settings.
This strategy is particularly useful when mutations on
several different genes can be associated with similar
clinical phenotypes, as occurs in Charcot-Marie-Tooth
disease and the various syndromes of defective glycopro-
tein synthesis. In these cases, conventional DNA se-
quencing of tens of genes becomes impractical as it is
expensive and time-consuming (5). Furthermore, in con-
trast to novel gene discovery, use of whole-exome se-
quencing to detect known pathogenic mutations does
not require overly specialized data analyses or further in
vitro experimental procedures to confirm their pathoge-
nicity.
The depth of coverage by whole-exome sequenc-
ing may not be enough to detect somatic mosaicism of
10%, so a negative test result does not completely rule
out NLRP3 somatic mosaicism in CAPS patients. In
retrospect, the small peak observed on the chromato-
gram obtained from Sanger sequencing associated with
the decrease of signal intensity of the wild-type allele
suggested the presence of this particular mutation in our
patient. However, the intensity of the small peak corre-
sponding to the NLRP3 mutated allele was extremely
low, falling within the baseline noise level, and was the
main reason for the false-negative call in the original
screen. Thus, whole-exome sequencing offers at least 3
powerful diagnostic advantages over other sequencing
methods in this context: 1) superior sensitivity over
Sanger sequencing for the detection of somatic gene
mosaicism, 2) rapid screening for other genes responsi-
ble for different monogenic autoinflammatory diseases
with overlapping clinical phenotypes, and 3) the poten-
tial to identify novel causal genes for CAPS-like pheno-
types, since genetic heterogeneity is highly likely in
CAPS.
In conclusion, we describe for the first time the
diagnostic use of whole-exome sequencing for the detec-
tion of somatic NLRP3 mosaicism in a patient with
CINCA syndrome. This observation highlights the diag-
nostic utility of whole-exome sequencing in patients with
CAPS. Securing a molecular diagnosis provides justifi-
cation for use of the clinically effective but expensive
lifelong therapies required to treat this condition.
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